Abstract:In recent years, there has been a large number of studies and reports about the efficacy and safety of recombinant human endostatin (rh-endostatin), an anti-angiogenic drug, in treatment of advanced lung cancer. Authentic assessment of rh-endostatin treatment in lung cancer is important. The aim of this study is to assess the clinical efficacy and safety of rh-endostatin combined with chemotherapy in the treatment of patients with non-small cell lung cancer (NSCLC).Cochrane systematic review methods were used in the data selection, and data were selected from the Cochrane Library, EMBASE, Medline, SCI, CBM, CNKI, and etc electronic database to get all clinical controlled trials. The retrieval time was March 2010. The objects of these randomized controlled trials were advanced NSCLC patients and in the experimental group was rh-endostatin combination chemotherapy, in the control group was chemotherapy alone to compare the efficacy of two groups. The quality of included trials were evaluated by two reviewers independently. The software RevMan 5.0 was used for meta-analyses.Fifteen trials with 1,326 patients were included according to the including criterion. All trials were randomized controlled trials, and two trials were adequate in reporting randomization. Thirteen trials didn't mention the blinding methods. Meta analysis indicated that the NPE arm (Vinorelbine+cisplatin+rh-endostatin) had a different response rate compared with NP (Vinorelbine+cisplatin) arm (OR=2.16, 95%CI: 1.57-2.99). The incidences of severe leukopenia (OR=0.94, 95%CI: 0.66-1.32) and severe thrombocytopenia (OR=1.00, 95%CI: 0.64-1.57) and nausea and vomiting (OR=0.85, 95%CI: 0.61-1.20) were similar in the NPE arm compared with those in the NP arm. The NPE plus radiotherapy (RT) arm had a similar response rate compared with NP plus RT arm (OR=2.39, 95%CI: 0.99-5.79). The incidences of leukopenia (OR=0.83, 95%CI: 0.35-1.94) and thrombocytopenia (OR=0.78, 95%CI: 0.19-3.16) and radiation esophagitis (OR=1.00, 95%CI: 0.40-2.49) were similar in the NPE plus RT arm compared with those in the NP plus RT arm.In the treatment of advanced NSCLC, rh-endostatin in combination with platinum-based chemotherapy improve the response rate without obviously raised side effects, however, when radiotherapy are added to NPE arm or NP arm, the response rates have a similar outcome. Owing to the small sample size and poor quality of included trials, more well-designed double-blinded randomized controlled trials should be performed.

Clinical Study on Recombinant Human Endostatin Combined with Cisplatin in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

P2.03a-005 A Study of Endostar Combined with Gemcitabine in the First-Line Treatment of the Elderly Patients with Advanced Non-Small Cell Lung Cancer

Recombinant Human Endostatin Combined with Platinum Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC

Clinical study on docetaxel combined with rh-endostatin in treatment of elderly advanced non-small cell lung cancer

Efficacy of Endostar Combined with Vinorelbine and Cisplatin in Treatment of Advanced Non-Small-cell Lung Cancer

Effectiveness and Safety of Recombinant Human Endostatin Combined with Concurrent Chemoradiotherapy for Advanced Non-small Cell Lung Cancer:a Meta-Analysis

P2.14-011 Recombinant Human Endostatin (endostar) Combined with Concurrent Intensity Modulated Radiation Therapy for Elderly Local Advanced NSCLC

Recombinant Human Endostatin Combined with Navelbine and Cisplatin in First Line Treatment of Advanced Non-Small Cell Lung Cancer

The Efficacy and Safety of Extended Use of Endostatin Plus Platinum-Based Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: an Analysis of a 10-Year Retrospective Study.

Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review]

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Clinical observation on the efficacy of Endostar combined with platin-based chemotherapy for 55 cases of advanced non-small cell lung cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

Efficacy of Platinum Drugs in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer and Their Effects on Prognosis and Survival.

Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer

Recombinant human endostatin combined carboplatin plus etoposide for advanced small-cell lung cancer.

Effect Of Thoracic Hyperthermic Perfusion With Recombinant Human Endostatin Plus Nedaplatin In Treating Pleural Effusion In Patients With Advanced Non-Small Cell Lung Cancer

Efficacy and Safety of Extended Use of Platinum-Based Doublet Chemotherapy Plus Endostatin in Patients with Advanced Nonsmall Cell Lung Cancer

Clinical Efficiency of Rh-Endostatin Combined with Vincristine and Cisplatin in the Treatment of Non-Small Cell Lung Cancer